Startseite Crystal structure of 2-chloro-4-fluorobenzyl (R)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H18ClFO3
Artikel Open Access

Crystal structure of 2-chloro-4-fluorobenzyl (R)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H18ClFO3

  • Guohua Chen ORCID logo EMAIL logo
Veröffentlicht/Copyright: 9. September 2024
Artikel downloaden (PDF)
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Zeitschrift für Kristallographie - New Crystal Structures
Aus der Zeitschrift Zeitschrift für Kristallographie - New Crystal Structures Band 239 Heft 6

Abstract

C21H18ClFO3, monoclinic, P21/c (no. 14), a = 34.657(5) Å, b = 6.0214(8) Å, c = 8.2301(11) Å, β = 93.883(5)°, V = 1713.5(4) Å3, Z = 4, Rgt (F) = 0.0683, wR ref (F 2) = 0.1435, T = 205(2) K.

CCDC no.: 2378364

Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.12 × 0.11 × 0.10 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.25 mm−1
Diffractometer, scan mode: Bruker APEX-II, φ and ω
θ max, completeness: 27.6°, >99 %
N(hkl)measured, N(hkl)unique, R int: 30,930, 3,940, 0.095
Criterion for I obs, N(hkl)gt: I obs > 2σ(I obs), 3,058
N(param)refined: 237
Programs: Bruker, 1 Olex2, 2 SHELX 3
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
C1 0.56867 (9) 0.6643 (6) 0.2273 (4) 0.0235 (7)
H1 0.559856 0.800577 0.183236 0.028*
C2 0.54551 (9) 0.5333 (6) 0.3171 (4) 0.0255 (7)
C3 0.55694 (9) 0.3314 (6) 0.3815 (4) 0.0254 (7)
H3 0.540310 0.246131 0.442098 0.031*
C4 0.59387 (9) 0.2575 (6) 0.3540 (3) 0.0197 (6)
H4 0.602112 0.118872 0.395847 0.024*
C5 0.61908 (8) 0.3827 (5) 0.2661 (3) 0.0178 (6)
C6 0.60570 (9) 0.5863 (6) 0.2046 (3) 0.0194 (6)
C7 0.65894 (8) 0.2981 (5) 0.2404 (4) 0.0191 (6)
H7A 0.661194 0.141883 0.273022 0.023*
H7B 0.664127 0.309462 0.125058 0.023*
C8 0.72348 (9) 0.4139 (5) 0.2960 (4) 0.0184 (6)
C9 0.75061 (9) 0.5581 (5) 0.4041 (4) 0.0194 (6)
H9 0.748188 0.510047 0.518034 0.023*
C10 0.73774 (9) 0.8004 (6) 0.3920 (4) 0.0262 (8)
H10A 0.737979 0.849733 0.279860 0.039*
H10B 0.755298 0.891514 0.460339 0.039*
H10C 0.711775 0.814028 0.428080 0.039*
C11 0.79217 (9) 0.5148 (5) 0.3638 (3) 0.0179 (6)
C12 0.81306 (8) 0.6578 (6) 0.2744 (3) 0.0185 (6)
H12 0.801849 0.792884 0.238691 0.022*
C13 0.85128 (8) 0.6062 (5) 0.2347 (3) 0.0166 (6)
C14 0.86826 (8) 0.4021 (5) 0.2886 (3) 0.0164 (6)
C15 0.84630 (9) 0.2582 (6) 0.3820 (3) 0.0184 (6)
H15 0.857114 0.122752 0.419161 0.022*
C16 0.80965 (9) 0.3126 (5) 0.4194 (3) 0.0191 (6)
H16 0.795793 0.214793 0.482722 0.023*
C17 0.90624 (9) 0.3481 (5) 0.2466 (3) 0.0180 (6)
H17 0.917794 0.214372 0.283389 0.022*
C18 0.92607 (9) 0.4908 (6) 0.1526 (3) 0.0189 (6)
C19 0.90920 (9) 0.6949 (5) 0.0995 (3) 0.0196 (7)
H19 0.923017 0.792041 0.035427 0.024*
C20 0.87305 (8) 0.7509 (6) 0.1408 (3) 0.0191 (6)
H20 0.862383 0.887895 0.106347 0.023*
C21 0.98148 (9) 0.2552 (6) 0.1569 (4) 0.0288 (8)
H21A 0.966883 0.127575 0.115182 0.043*
H21B 0.983216 0.251878 0.274962 0.043*
H21C 1.007280 0.251069 0.118051 0.043*
Cl1 0.63552 (2) 0.74993 (15) 0.09212 (9) 0.02457 (19)
F1 0.50929 (6) 0.6088 (4) 0.3409 (3) 0.0400 (6)
O1 0.68645 (6) 0.4323 (4) 0.3386 (2) 0.0201 (5)
O2 0.73216 (6) 0.2976 (4) 0.1861 (3) 0.0278 (6)
O3 0.96238 (6) 0.4547 (4) 0.1014 (3) 0.0225 (5)

1 Source of materials

Naproxen acylchloride was synthesized according to the literature method. 4 2-Chloro-4-fluorobenzyl alcohol (0.01 mol, 1.60 g) and 4-(dimethylamino)-pyridin (DMAP, 0.0015 mol, 0.18 g) were dissolved in dry tetrahydrofuran (20 mL) and triethylamine (0.015 mol, 2 mL). The solution of naproxen acylchloride in dry tetrahydrofuran was dropwise added at 0 °C. The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was filtrated to remove the solid and the filtrate was concentrated under vacuum to remove the solvent. The residue was dissolved in dichloromethane, successively washed with 5 % NaOH solution and water to pH = 7, and dried with anhydrous Na2SO4 The solution was filtrated, and concentrated under vacuum to obtain crude product. The crude product was purified by recrystallization in ethanol. The crystals were obtained from tetrahydrofuran solution.

2 Experimental details

The U iso values of hydrogen atoms were set to be 1.5U eq of the carrier atom for methyl H atoms and 1.2U eq for the remaining H atoms.

3 Comment

Naproxen, a powerful non-steroidal anti-inflammatory drug (NSAID), inhibits both COX-1 and COX-2 enzymes, essential elements of the cyclooxygenase pathway. Naproxen frequently induces gastrointestinal issues, including gastroduodenal ulcers. The carboxyl group in naproxen might be responsible for these adverse effects. Studies indicate that modifying this carboxyl group through esterification can lessen these gastrointestinal reactions. 5 , 6 Naproxen is presently employed in clinical settings to manage or mitigate pain and inflammation associated with conditions like rheumatoid arthritis 7 and gout. 8 Moreover, it has certain therapeutic effects on migraines 9 but may cause certain side effects. Additionally, research indicates that naproxen has a preventive effect on Lynch syndrome. 10 Consequently, creating derivatives of naproxen that have reduced side effects is crucial.

The title compound contains one naphthyl ring and one phenyl ring. The bond distances of C–O are 1.453(3) Å (C7–O1), 1.358(4) Å (C8–O1), 1.198(4) Å (C8–O2), 1.371(4) Å (C18–O3) and 1.431(4) Å (C21–O3). The bond distance of C8–O2 are shorter than others, indicating a double bond. The bond distance of C–Cl are 1.739(3) Å (C6–Cl1) and the bond distance of C–F are 1.362(4) Å (C2–F1). The dihedral angels of ring 1 (C1–C2–C3–C4–C5–C6) and ring 2 (C11–C12–C13–C14–C15–C16), ring 1 (C1–C2–C3–C4–C5–C6) and ring 3 (C13–C14–C17–C18–C19–C20), and ring 2 (C11–C12–C13–C14–C15–C16) and ring 3 (C13–C14–C17–C18–C19–C20) are 0.8(1)°, 2.1(1)° and 1.33(8)°. The other bond distances and angles are in their normal ranges according to the previously reported compounds. 11 , 12

Corresponding author: Guohua Chen, Liao cheng Vocational and Technical College, Liao cheng, 252000, China, E-mail:

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

  3. Research funding: None declared.

References

1. Bruker. SAINT and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2000.Suche in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8, https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

4. Huang, Z.; Velázquez, C. A.; Abdellatif, K. R. A.; Chowdhury, M. A.; Reisz, J. A.; DuMond, J. F.; King, S. B.; Knaus, E. E. Ethanesulfohydroxamic Acid Ester Prodrugs of Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Synthesis, Nitric Oxide and Nitroxyl Release, Cyclooxygenase Inhibition, Anti-inflammatory, and Ulcerogenicity Index Studies. J. Med. Chem. 2011, 54, 1356–1364; https://doi.org/10.1021/jm101403g.Suche in Google Scholar PubMed

5. Ullah, N.; Huang, Z.; Sanaee, F.; Rodriguez-Dimitrescu, A.; Aldawsari, F.; Jamali, F.; Bhardwaj, A.; Islam, N. U.; Velázquez-Martínez, C. A. NSAIDs Do Not Require the Presence of a Carboxylic Acid to Exert Their Anti-inflammatory Effect – Why Do We Keep Using it? J. Enzyme Inhib. Med. Chem. 2015, 31, 1018–1028; https://doi.org/10.3109/14756366.2015.1088840.Suche in Google Scholar PubMed

6. de Carvalho Bertozo, L.; Tadeu, H. C.; Sebastian, A.; Maszota-Zieleniak, M.; Samsonov, S. A.; Ximenes, V. F. Role for Carboxylic Acid Moiety in NSAIDs: Favoring the Binding at Site II of Bovine Serum Albumin. Mol. Pharmaceutics 2024, 21, 2501–2511; https://doi.org/10.1021/acs.molpharmaceut.4c00044.Suche in Google Scholar PubMed

7. Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Naproxen up to Date: A Review of its Pharmacological Properties and Therapeutic Efficacy and Use in Rheumatic Diseases and Pain States. Drugs 1979, 18, 241–277; https://doi.org/10.2165/00003495-197918040-00001.Suche in Google Scholar PubMed

8. Janssens, H. J.; Janssen, M.; van de Lisdonk, E. H.; van Riel, P. L.; van Weel, C. Use of Oral Prednisolone or Naproxen for the Treatment of Gout Arthritis: A Double-Blind, Randomised Equivalence Trial. Lancet 2008, 371, 1854–1860; https://doi.org/10.1016/s0140-6736(08)60799-0.Suche in Google Scholar PubMed

9. Suthisisang, C. C.; Poolsup, N.; Suksomboon, N.; Lertpipopmetha, V.; Tepwitukgid, B. Meta-Analysis of the Efficacy and Safety of Naproxen Sodium in the Acute Treatment of Migraine. Headache 2010, 50, 808–818; https://doi.org/10.1111/j.1526-4610.2010.01635.x.Suche in Google Scholar PubMed

10. Reyes-Uribe, L.; Wu, W.; Gelincik, O.; Bommi, P. V.; Francisco-Cruz, A.; Solis, L. M.; Lynch, P. M.; Lim, R.; Stoffel, E. M.; Kanth, P.; Samadder, N. J.; Mork, M. E.; Taggart, M. W.; Milne, G. L.; Marnett, L. J.; Vornik, L.; Liu, D. D.; Revuelta, M.; Chang, K.; Vilar, E.; Kopelovich, L.; Wistuba, I. I.; Lee, J. J.; Sei, S.; Shoemaker, R. H.; Szabo, E.; Richmond, E.; Umar, A.; Perloff, M.; Brown, P. H.; Lipkin, S. M. Naproxen Chemoprevention Promotes Immune Activation in Lynch Syndrome Colorectal Mucosa. Gut 2020, 70, 555–566; https://doi.org/10.1136/gutjnl-2020-320946.Suche in Google Scholar PubMed PubMed Central

11. Liang, D.; Yang, X. H.; Sun, W.; Wang, W. N.; Yang, J. Z.; Liu, Y. Y.; Wang, G. S. Synthesis, Crystal Structure and Biological Activities of Naproxen-Eugenol Ester Progrug. Chem. Res. Chin. Univ . 2013, 29, 245–248; https://doi.org/10.1007/s40242-013-2266-9.Suche in Google Scholar

12. Hashimoto, M.; Nakamura, Y.; Hamada, K. Structure of 4-Chlorobenzyl Alcohol. Acta Crystallogr. 1988, C44, 482–484; https://doi.org/10.1107/s0108270187010965.Suche in Google Scholar
Received: 2024-06-24
Accepted: 2024-08-19
Published Online: 2024-09-09
Published in Print: 2024-12-17

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 3-nitrophenol-2,1,3-benzoselenadiazole (1/1), C12H9N3O3Se
  4. Crystal structure of diaqua-(hydroxido)-{μ-[2-(hydroxy)-5-[(4-nitrophenyl)diazenyl]benzoato]}-{2-hydroxy-5-[(4-nitrophenyl)diazenyl]benzoato}-(1,10-phenanthroline)-diterbium hydrate, C38H27.4N8O12.2Tb
  5. Crystal structure of poly[bis(μ3-3-fluoro-4-(1H-1,2,4-triazol-1-yl)benzoato-κ3 O:O′:N)cadmium(II)] – dimethylformamide (1/1), C21H17CdF2N7O5
  6. The crystal structure of 2-amino-N-(pyridin-2-yl)benzamide, C12H11N3O
  7. The crystal structure of 2,3-di(pyridin-2-yl)-2,3-dihydroquinazolin-4(1H)-one, C18H14N4O
  8. Crystal structure of 2-chloro-4-fluorobenzyl (R)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H18ClFO3
  9. Crystal structure of [1-(4-carboxyphenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylic acid]-(methylsulfinyl)methane, C15H16N2O6S
  10. The crystal structure of 2-ethyl-1,1-dimethyl-1H-benzo[e]indole, C16H17N
  11. The crystal structure of (Z)-5-amino-N ′-hydroxy-1H-pyrazole-4-carboximidamide, C4H7N5O
  12. The crystal structure of 2,2,5-trimethyl-3-(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)phenyl)imidazolidin-4-one, C24H24N4O2S
  13. The crystal structure of tetrakis(μ2-acetato-κ2 O:O′)-bis[(4′-phenyl-4,2′:6′,4″-terpyridine-κ1 N)dicopper(II)], C25H21CuN3O4
  14. Crystal structure of poly(3-thiophenecarboxylato-κ 3 O,O′:O′)-(methanol-κO)cadmium(II), C11H10O5S2Cd
  15. The crystal structure of dichloridobis[4′-(p-methoxylphenyl)-4,2′:6′,4″-terpyridine-κN] zinc(II), C44H34Cl2N6O2Zn
  16. The crystal structure of 1-(2-carboxyethyl)-1H-imidazole 3-oxide
  17. Crystal structure of 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-(((E)-pyridin-2-ylmethylene)amino)phenyl)urea), C45H47N13O4
  18. Crystal structure of a (E)-4-bromo-N-(4-(diethylamino)-2-hydroxybenzylidene) benzenaminium acetate ─ 4-bromoaniline (1/1)
  19. Crystal structure of 2,2′-(iminobis(methylene))bis(benzimidazolium) bis(p-toluenesulfonate), C30H31N5O6S2
  20. The crystal structure of alogliptinium meta-chlorobenzoate
  21. Crystal structure of 4-bromobenzyl 2-(6-methoxy-naphthalen-2-yl)propanoate, C21H19BrO3
  22. The hydrated double salt structure of (E)-4-(2-benzylidenehydrazine-1-carbonyl)pyridin-1-ium cation with 2-hydroxybenzoate and benzoate anions
  23. Crystal structure of (R)(R)-5-chloro-3-((S,1E,3E)-3,5-dimethyl-hepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate, C21H24ClNO4
  24. The crystal structure of bis(3-oxo-1,3-diphenylprop-1-en-1-olato-κ 2 O:O′)-bis(1,4-dioxane-κ 1 O)nickel(II), C38H38O8Ni
  25. Crystal structure of poly[aqua-(pyridine-3-carboxylato-κ1 N)(pyridine-3-carboxylato-κ2 O,O′) cadmium(II)] dihydrate, C12H14N2O7Cd
  26. The crystal structure of 4-(4-phenyl-5-(((1-(2,4,6-tribromophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-4H-1,2,4-triazol-3-yl)pyridine, C22H14Br3N7S
  27. The crystal structure of N-benzylquinoline-2-carbothioamide, C17H14N2S
  28. Crystal structure of bis(3-isopropylphenyl)-4,4′-bipyridinium dichloride dihydrate, C28H30N2⋅2Cl⋅2H2O
  29. The crystal structure of ethyl 2-amino-4-(cyanophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C19H18N2O4
  30. Crystal structure of (4R,10S)-6-hydroxy-7-isopropyl-4,10-dimethyl-1,2,3,5-hexahydro-6,10-epoxyazulen-9-one, C15H22O3
  31. The crystal structure of (E)-(2-(2-hydroxy-3-methoxybenzylidene)aminophenyl)arsonic acid, C14H14AsNO5
  32. The crystal structure of poly[(μ 2-2-aminoisophthalato-κ4O,O′:O″:O″′)-(N-methylpyrrolidone κ1O)-dioxido-uranium(VI)], C13H14N2O7U
  33. The crystal structure of the co-crystal isonicotinamide · terephthalic acid, C8H6O4·2(C6H6N2O)
  34. The crystal structure of (E)-1-phenyl-3-(p-tolylthio)but-2-en-1-one, C17H16OS
  35. The crystal structure of 4,5-bis((Z)-chloro(hydroxyimino)methyl)-1H-imidazol-3-ium chloride monohydrate
  36. The crystal structure of 1,2-bis(4-(dimethylamino)phenyl)ethane-1,2-dione. C18H20N2O2
  37. Crystal structure of 2-chloro-4-fluorobenzyl 2-acetoxybenzoate, C16H12ClFO4
  38. Crystal structure of methyl 1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate, C19H14N2O2
  39. Crystal structure of (3-(dimethoxymethyl)-5-methoxy-1H-indol-1-yl)(5-fluoro-2-iodophenyl)methanone, C19H17FINO4
  40. Crystal structure of tetrachlorido-bis(1-[(1H-triazole-1-yl)methyl]-1H-benzotriazole-κ2 N:N′)dicopper, C36H32Cu2N24Cl4
  41. Crystal structure of 2-(2,3-bis(4-methoxyphenyl)-1H-pyrrolo[2,3-b]quinoxalin-1-yl)anilin, C30H24N4O2
  42. Crystal structure of 5,7-dihydroxy-2-phenyl-4H-chromen-4-one–N,N-dimethylformamide(1/1), C18H17NO5
  43. The crystal structure of bis(μ 2-biphenyl-2,2′-dicarboxylato)-diaqua-bis(nitrato)-bis(2,2′:6′,2′′-terpyridine)dineodymium(III), C46H32I2N8Nd2O16
  44. Crystal structure of (Z)-4-amino-N ′-((4-chlorophenyl)(phenyl)methylene)benzohydrazide, C20H16ClN3O
  45. Crystal structure of (E)-6,8-dimethoxy-4-(4-morpholinobenzylidene)-3,4-dihydro-1-benzoxepin-5(2H)-one, C23H25NO5
  46. Crystal structure of (R)-2-((3-(3-aminopiperidin-1-yl)-6-methyl-5-oxo-1,2,4-triazin-4(5H)-yl) methyl)-4-fluorobenzonitrile benzoate monohydrate, C24H27FN6O4
  47. The crystal structure of [triaqua-(8-carboxymethoxy-quinoline-2-carboxylato-κ 3 N,O,O)copper(II)]monohydrate, C12H15NO9Cu
  48. Crystal structure of (((4-chlorophenyl)sulfonyl)glycinato-κ 2 N,O)bis(1,10-phenanthroline-κ 2 N,N′)cobalt(II) tetrahydrate, C32H30ClCoN5O8S
  49. Crystal structure of (((3-nitrophenyl)sulfonyl)-β-alaninato-κO)bis(2,2′-bipyridine-κ 2 N, N′)copper(II) 3-nitrobenzenesulfonate, C35H29CuN7O11S2
  50. Crystal structure of 3-phenoxybenzyl 2-(6-methoxynaphthalen-2-yl)propanoate, C27H24O4
  51. 6-(2′,3′-Dihydroxy-3′-methylbutyl)-7-methoxy-8-(3″-methylbut-2″-en-1″-yl)-2H-chromen-2-one, C20H26O5
  52. Crystal structure of bromido-(2,2′:6′,2″-terpyridine-4′-onato-κ3N)palladium(II) methanol solvate
  53. The crystal structure of ethyl 2-amino-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C20H22N2O6
  54. Crystal structure of (1E,3E,5E)-1,6-bis(4-(pentyloxy)phenyl)hexa-1,3,5-triene, C28H36O2
  55. The crystal structure of tris(2-bromo-4-methylphenyl)amine, C21H18Br3N
  56. The crystal structure of 3-(2,5-dimethylanilino)-1-(2,5-dimethylphenyl)-4-methyl-1H-pyrrole-2,5-dione, C21H22N2O2
  57. Crystal structure of dicarbonyl (μ2-indole-2-carboxylato κ2 O:O′)tris(triphenylarsine-κAs)dirhodium(I) acetone solvate, C68H56As3NO5Rh2
  58. The crystal structure of 4-chloro-2-formylphenyl 4-methylbenzenesulfonate, C14H11ClO4S
  59. Crystal structure of 4-iodobenzyl 2-(6-methoxynaphthalen-2-yl) propanoate, C21H19IO3
https://doi.org/10.1515/ncrs-2024-0259
Creative Commons
BY 4.0

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 3-nitrophenol-2,1,3-benzoselenadiazole (1/1), C12H9N3O3Se
  4. Crystal structure of diaqua-(hydroxido)-{μ-[2-(hydroxy)-5-[(4-nitrophenyl)diazenyl]benzoato]}-{2-hydroxy-5-[(4-nitrophenyl)diazenyl]benzoato}-(1,10-phenanthroline)-diterbium hydrate, C38H27.4N8O12.2Tb
  5. Crystal structure of poly[bis(μ3-3-fluoro-4-(1H-1,2,4-triazol-1-yl)benzoato-κ3 O:O′:N)cadmium(II)] – dimethylformamide (1/1), C21H17CdF2N7O5
  6. The crystal structure of 2-amino-N-(pyridin-2-yl)benzamide, C12H11N3O
  7. The crystal structure of 2,3-di(pyridin-2-yl)-2,3-dihydroquinazolin-4(1H)-one, C18H14N4O
  8. Crystal structure of 2-chloro-4-fluorobenzyl (R)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H18ClFO3
  9. Crystal structure of [1-(4-carboxyphenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylic acid]-(methylsulfinyl)methane, C15H16N2O6S
  10. The crystal structure of 2-ethyl-1,1-dimethyl-1H-benzo[e]indole, C16H17N
  11. The crystal structure of (Z)-5-amino-N ′-hydroxy-1H-pyrazole-4-carboximidamide, C4H7N5O
  12. The crystal structure of 2,2,5-trimethyl-3-(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)phenyl)imidazolidin-4-one, C24H24N4O2S
  13. The crystal structure of tetrakis(μ2-acetato-κ2 O:O′)-bis[(4′-phenyl-4,2′:6′,4″-terpyridine-κ1 N)dicopper(II)], C25H21CuN3O4
  14. Crystal structure of poly(3-thiophenecarboxylato-κ 3 O,O′:O′)-(methanol-κO)cadmium(II), C11H10O5S2Cd
  15. The crystal structure of dichloridobis[4′-(p-methoxylphenyl)-4,2′:6′,4″-terpyridine-κN] zinc(II), C44H34Cl2N6O2Zn
  16. The crystal structure of 1-(2-carboxyethyl)-1H-imidazole 3-oxide
  17. Crystal structure of 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-(((E)-pyridin-2-ylmethylene)amino)phenyl)urea), C45H47N13O4
  18. Crystal structure of a (E)-4-bromo-N-(4-(diethylamino)-2-hydroxybenzylidene) benzenaminium acetate ─ 4-bromoaniline (1/1)
  19. Crystal structure of 2,2′-(iminobis(methylene))bis(benzimidazolium) bis(p-toluenesulfonate), C30H31N5O6S2
  20. The crystal structure of alogliptinium meta-chlorobenzoate
  21. Crystal structure of 4-bromobenzyl 2-(6-methoxy-naphthalen-2-yl)propanoate, C21H19BrO3
  22. The hydrated double salt structure of (E)-4-(2-benzylidenehydrazine-1-carbonyl)pyridin-1-ium cation with 2-hydroxybenzoate and benzoate anions
  23. Crystal structure of (R)(R)-5-chloro-3-((S,1E,3E)-3,5-dimethyl-hepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate, C21H24ClNO4
  24. The crystal structure of bis(3-oxo-1,3-diphenylprop-1-en-1-olato-κ 2 O:O′)-bis(1,4-dioxane-κ 1 O)nickel(II), C38H38O8Ni
  25. Crystal structure of poly[aqua-(pyridine-3-carboxylato-κ1 N)(pyridine-3-carboxylato-κ2 O,O′) cadmium(II)] dihydrate, C12H14N2O7Cd
  26. The crystal structure of 4-(4-phenyl-5-(((1-(2,4,6-tribromophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-4H-1,2,4-triazol-3-yl)pyridine, C22H14Br3N7S
  27. The crystal structure of N-benzylquinoline-2-carbothioamide, C17H14N2S
  28. Crystal structure of bis(3-isopropylphenyl)-4,4′-bipyridinium dichloride dihydrate, C28H30N2⋅2Cl⋅2H2O
  29. The crystal structure of ethyl 2-amino-4-(cyanophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C19H18N2O4
  30. Crystal structure of (4R,10S)-6-hydroxy-7-isopropyl-4,10-dimethyl-1,2,3,5-hexahydro-6,10-epoxyazulen-9-one, C15H22O3
  31. The crystal structure of (E)-(2-(2-hydroxy-3-methoxybenzylidene)aminophenyl)arsonic acid, C14H14AsNO5
  32. The crystal structure of poly[(μ 2-2-aminoisophthalato-κ4O,O′:O″:O″′)-(N-methylpyrrolidone κ1O)-dioxido-uranium(VI)], C13H14N2O7U
  33. The crystal structure of the co-crystal isonicotinamide · terephthalic acid, C8H6O4·2(C6H6N2O)
  34. The crystal structure of (E)-1-phenyl-3-(p-tolylthio)but-2-en-1-one, C17H16OS
  35. The crystal structure of 4,5-bis((Z)-chloro(hydroxyimino)methyl)-1H-imidazol-3-ium chloride monohydrate
  36. The crystal structure of 1,2-bis(4-(dimethylamino)phenyl)ethane-1,2-dione. C18H20N2O2
  37. Crystal structure of 2-chloro-4-fluorobenzyl 2-acetoxybenzoate, C16H12ClFO4
  38. Crystal structure of methyl 1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate, C19H14N2O2
  39. Crystal structure of (3-(dimethoxymethyl)-5-methoxy-1H-indol-1-yl)(5-fluoro-2-iodophenyl)methanone, C19H17FINO4
  40. Crystal structure of tetrachlorido-bis(1-[(1H-triazole-1-yl)methyl]-1H-benzotriazole-κ2 N:N′)dicopper, C36H32Cu2N24Cl4
  41. Crystal structure of 2-(2,3-bis(4-methoxyphenyl)-1H-pyrrolo[2,3-b]quinoxalin-1-yl)anilin, C30H24N4O2
  42. Crystal structure of 5,7-dihydroxy-2-phenyl-4H-chromen-4-one–N,N-dimethylformamide(1/1), C18H17NO5
  43. The crystal structure of bis(μ 2-biphenyl-2,2′-dicarboxylato)-diaqua-bis(nitrato)-bis(2,2′:6′,2′′-terpyridine)dineodymium(III), C46H32I2N8Nd2O16
  44. Crystal structure of (Z)-4-amino-N ′-((4-chlorophenyl)(phenyl)methylene)benzohydrazide, C20H16ClN3O
  45. Crystal structure of (E)-6,8-dimethoxy-4-(4-morpholinobenzylidene)-3,4-dihydro-1-benzoxepin-5(2H)-one, C23H25NO5
  46. Crystal structure of (R)-2-((3-(3-aminopiperidin-1-yl)-6-methyl-5-oxo-1,2,4-triazin-4(5H)-yl) methyl)-4-fluorobenzonitrile benzoate monohydrate, C24H27FN6O4
  47. The crystal structure of [triaqua-(8-carboxymethoxy-quinoline-2-carboxylato-κ 3 N,O,O)copper(II)]monohydrate, C12H15NO9Cu
  48. Crystal structure of (((4-chlorophenyl)sulfonyl)glycinato-κ 2 N,O)bis(1,10-phenanthroline-κ 2 N,N′)cobalt(II) tetrahydrate, C32H30ClCoN5O8S
  49. Crystal structure of (((3-nitrophenyl)sulfonyl)-β-alaninato-κO)bis(2,2′-bipyridine-κ 2 N, N′)copper(II) 3-nitrobenzenesulfonate, C35H29CuN7O11S2
  50. Crystal structure of 3-phenoxybenzyl 2-(6-methoxynaphthalen-2-yl)propanoate, C27H24O4
  51. 6-(2′,3′-Dihydroxy-3′-methylbutyl)-7-methoxy-8-(3″-methylbut-2″-en-1″-yl)-2H-chromen-2-one, C20H26O5
  52. Crystal structure of bromido-(2,2′:6′,2″-terpyridine-4′-onato-κ3N)palladium(II) methanol solvate
  53. The crystal structure of ethyl 2-amino-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C20H22N2O6
  54. Crystal structure of (1E,3E,5E)-1,6-bis(4-(pentyloxy)phenyl)hexa-1,3,5-triene, C28H36O2
  55. The crystal structure of tris(2-bromo-4-methylphenyl)amine, C21H18Br3N
  56. The crystal structure of 3-(2,5-dimethylanilino)-1-(2,5-dimethylphenyl)-4-methyl-1H-pyrrole-2,5-dione, C21H22N2O2
  57. Crystal structure of dicarbonyl (μ2-indole-2-carboxylato κ2 O:O′)tris(triphenylarsine-κAs)dirhodium(I) acetone solvate, C68H56As3NO5Rh2
  58. The crystal structure of 4-chloro-2-formylphenyl 4-methylbenzenesulfonate, C14H11ClO4S
  59. Crystal structure of 4-iodobenzyl 2-(6-methoxynaphthalen-2-yl) propanoate, C21H19IO3
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2024-0259/html
Button zum nach oben scrollen